Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
  • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
  • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/04—Macromolecular materials
  • A61L31/042—Polysaccharides

Definitions

• the present invention relates to a method of temporariiy insolubilizing films and gels of N-carboxyalkyl derivatives of chitosan to provide materials which can have varied degradation times for various biomedical applications such as adhesion prevention. More particularly, the method relates to an annealing process in which the material is insoiubilized by exposing film to temperatures between 50°C and 200°C for various lengths of time.
• Chitin and chitosan are well known biocompatible materials whose preparation has been described in U.S. Patent 2,040,880, which issued on May 19, 1936.
• the preparation of another chitosan derivative, N-carboxybutyl chitosan is described in U.S. Patent 4,835,265.
• scar tissue results from the organization of fibrinous exudate on tissue surfaces due to the infliction of trauma or inflammation.
• Vital tissues such as blood vessels, or organs including the kidney, liver, and intestines are coated with mucous or serous membranes so that they can function independently of each other.
• mucous or serous membranes are the body wall pleura and the organ pleura in the thoracic cavity and the parietal peritoneum and mesentery in the abdominal cavity, each protecting the corresponding organs.
• Surgical trauma or inflammation in those portions of the body coated with serous membranes could result in the build up of fibrinous exudate regardless of the size of the affected part.
• Adhesions occur in the orthopedics field where conditions such as acute or chronic arthritis, suppurative, rheumatoid, gonorrheal, or tuberculous arthritis, or traumatic injuries at the joint, such as fracture or sprain, result in ankylotic diseases wherein the surface of the bones constituting the joint adhere to each other and thereby restrict the mobility of the joint.
• congenital radioulnar syntosis wherein a spoke bone and an ulna adhere together, is difficult to remedy by a surgical operation, since the separated bones frequently re-adhere.
• Adhesions are also prominent in tendon surgery. In this instance, there is a general tendency towards adhesion between the tendon and the surrounding sheath or other surroun ⁇ ding tissue during an immobilization period following the operation.
• the laminectomy membrane is a well organized mass of fibrinous tissue which replaces the bone that was removed at the laminectomy. This fibrinous mass binds the dura to the overlying muscles. This causes narrowing of the spinal canal which places pressure on the cauda equina or nerve roots. This scar tissue formation may require reoperation which is tedious and dangerous leading to the possibility of dural tears and the damage to the emergent nerve roots resulting in motor weakness, sensory change, and painful paresthesia.
• N-carboxyalkyl derivatives of chitosan is dissolved in a neutral pH aqueous solution or a slightly acidic solution.
• the solution is then cast and dried to form a thin clear film.
• the solution is poured into a mold (for example a petri dish) and lyophilized to form a sponge-type film with varying dimensions depending on the mold, the solution concentration, and the solution volume.
• the resulting films are insolubilized by an annealing process in which they are exposed to temperatures between 50°C and 200°C for various periods of time depending on the desired length of insolubilization time, and ultimately bioresorption time.
• the biodegradable polymer films to be used to inhibit fibrin formation and organization are materials which will eventually revert to the gel or solution state and ultimately be resorbed and metabolized by the body. As taught in co-pending application Serial Number 07/644,758, these materials include amino N-carboxyalkyl derivatives of chitosan. Chitosan is a partially deacetylated chitin defined for the purposes herein as being greater than 50% deacetylated.
• N-carboxyalkyl derivatives used in the present invention are water soluble polymers which have not been crosslinked to form insoluble materials.
• these materials are N-carboxymethyl chitosan, N-carboxybutyl chitosan, N,O carboxymethyl chitosan, and N,O-carboxybutyI chitosan, N-carboxy- ethyl chitosan, N.O-carboxyethyl chitosan, N,O-carboxypropyl chitosan, and N-carboxypropyl chitosan.
• these materials can be temporarily insolubilized to form substances which will begin to degrade in a period of from 2-5 days to up to one year t ⁇ vitro.
• these polymers would be in the form of a film, sponge, or woven sheet which will break down into visco-elastic materials.
• these would be the use of N,O-carboxymethyl chitosan or N-carboxy- butyl chitosan films insolubilized by annealing with heat as described herein. While the exact mechanism which causes the insolubilization of the materials is unclear, it is postulated that either a dehydration mechanism, or a crystallization mechanism or a combination of the two is causing this phenomena.
• Additives such as anti-thrombogenic materials may be added to the films before insolubilizing.
• the materials may be formed into a viscous gel for injection into the affected location to prevent fibrinous buildup.
• This gel could be used for applications where a shorter in_ vivo residence time is desired and/or the location would best be suited for prevention of adhesions with a material in this form.
• the gels may be formed by placing the insolubilized films in a sterile aqueous media and heating the solution to increased temperatures until the film hydrates and swells to form a gelatinous mass.
• the degree of insolubilization of the viscous gels can be varied by varying the temperature of the aqueous solution and the extent of time the film is allowed to remain in the solution.
• the present invention has the added advantage that the insolubilization step can be done during the heat or steam sterilization of the device, if desired.
• the resulting solution was then rendered free of all low molecular weight impurities by extensive dialysis with water via a 300K molecular weight cutoff membrane (Filtron - Norwood, MA) on the same ultra-filtration device. Films were then formed from this solution by both casting (allowing evaporation) on a non-stick surface such as a glass petri dish, or a piece of mylar film and by freeze drying by adding 300 ml of the solution to a 90 mm diameter disposable petri dish and lyophilized in a tray dryer for 72 hours at -50°C. The resulting films (either cast or freeze dried) were then insolubilized by placing the film into an oven at 121° c for 20 minutes (correlating to a standard autoclave cycle). Both films were placed in aqueous media and dissolved within 5 days. Based on the dissolution which did occur, the film would dissolve in approximately two months.
• Example 2 Three films were prepared as described above in Example 1 by casting in a petri dish. Each was exposed to a different temperature for a period of 30 minutes. The first was heated at 76°C, the second at 121 °C and the third at 168°C. One f ⁇ m was cast and not treated. This served as a control.
• the four films were placed in 5 cc of PBS and placed in an incubator at 37°C. At various times, the samples were removed and observed visually for solubility. Following this the incubation medium was removed from the dish and analyzed for soluble product via size exclusion chromatography. The control film was completely solubilized within one day. The film at 76°C indicated complete solubility between 1-2 days. The 121 °C treated film indicated complete solubility at 4-5 days, while the film treated at 168°C indicated no evidence of solubility up to 14 days.
• Example 2 Three films were prepared as described above in Example 1 with the exception that the temperature of annealing was kept constant at 121 °C and the exposure time was varied between 15 minutes and 23 hours. Again, a non-treated film served as a control. AH films were evaluated as mentioned above. The film treated at 15 minutes indicated complete solubility in 2-3 days, the film treated for 60 minutes indicated solubility through 1 days (complete solubility had not yet been attained) while the film treated at 2 hours indicated no solubility in an excess of 14 days.
• the degradation of the films / ⁇ vivo could be lengthened by increasing the annealing time and temperature.
• a film which would degrade within 14 days is desirable and may be attained by annealing at 121 °C for about 60 minutes.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Vascular Medicine (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Materials Engineering (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Materials For Medical Uses (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Cosmetics (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25208800

Family Applications (1)

Country Status (5)

Cited By (7)

Citations (3)

• 1992
  • 1992-12-08 JP JP5511669A patent/JPH0826081B2/ja not_active Expired - Lifetime
  • 1992-12-08 AU AU32355/93A patent/AU3235593A/en not_active Abandoned
  • 1992-12-08 WO PCT/US1992/010417 patent/WO1993013137A1/en not_active Application Discontinuation
  • 1992-12-08 EP EP93900814A patent/EP0617707A1/en not_active Withdrawn
  • 1992-12-08 CA CA002125402A patent/CA2125402A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events